Acute Promyelocytic Leukemia with i(17)(q10)

Similar documents
Fluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)

Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328

Role of FISH in Hematological Cancers

KJLM. A Rare Case of Microgranular Acute Promyelocytic Leukemia Associated with ider(17)(q10)t(15;17) in an Old-age Patient INTRODUCTION CASE REPORT

CYTOGENETICS Dr. Mary Ann Perle

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota

Identification of PML/RARα fusion gene transcripts that showed no t(15;17) with conventional karyotyping and fluorescent in situ hybridization

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities

Chromosome Abnormalities

HEMATOLOGIC MALIGNANCIES BIOLOGY

Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010

Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED

Chronic myeloid leukemia (CML)

Research Article FISH Detection of PML-RARA Fusion in ins(15;17) Acute Promyelocytic Leukaemia Depends on Probe Size

A. Incorrect! All the cells have the same set of genes. (D)Because different types of cells have different types of transcriptional factors.

Hematopathology Case Study

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Acute Lymphoblastic and Myeloid Leukemia

Myeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:

Leukaemia Section Review

Case #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed

Fluorescent in situ hybridization studies in multiple myeloma

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

MOLECULAR AND CLINICAL ONCOLOGY 3: , 2015

Patterns of BCR/ABL Gene Rearrangements by Fluorescence in Situ Hybridization (FISH) in Chronic Myeloid Leukaemia

Hematopathology Case Study

Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+)

Molecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang

Acute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg

Test Name Results Units Bio. Ref. Interval. Positive

Case Report Blasts-more than meets the eye: evaluation of post-induction day 21 bone marrow in CBFB rearranged acute leukemia

Heme 9 Myeloid neoplasms

An Overview of Cytogenetics. Bridget Herschap, M.D. 9/23/2013

Haematology Probes for Multiple Myeloma

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Hematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD

Myelodysplastic Syndrome Case 158

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information

Promyelocytic sarcoma of the sternum: a case report and review of the literature

Case Report RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia

Introduction. of some recurrent aberrations, for example, 8, del(9q), or CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS

Test Name Results Units Bio. Ref. Interval. Positive

Chromosomal Aberrations

Belgium recommendations for the management of acute promyelocytic leukaemia

Case Workshop of Society for Hematopathology and European Association for Haematopathology

Chromosome Structure & Recombination

HEMATOPATHOLOGY SUMMARY REPORT RL;MMR;

MS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi

If unqualified, Complete remission is considered to be Haematological complete remission

If unqualified, Complete remission is considered to be Haematological complete remission

WBCs Disorders 1. Dr. Nabila Hamdi MD, PhD

Supplementary Appendix

Do acgh analysis have a place in routine cytogenetic workup in leukemia/cancer? - A single institution experience. Cambridge, April 9 th 2013

Test Name Results Units Bio. Ref. Interval. Positive

Addressing the challenges of genomic characterization of hematologic malignancies using microarrays

A pediatric patient with acute leukemia of ambiguous lineage with a NUP98-NSD1 rearrangement SH

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Leukaemia Section Review

Understanding the Human Karyotype Colleen Jackson Cook, Ph.D.

Fluorescence in-situ Hybridization (FISH) A Rapid and Useful Technique for Diagnosis and Management in Leukemia

PETHEMA; 2 HOVON; 3 PLAG and 4 GATLA Groups.

Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation

Oncology Genetics: Cytogenetics and FISH 17/09/2014

Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML

Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach

Mixed Phenotype Acute Leukemias

Volume 7, Issue 1 January 2012

급성전골수구백혈병환자의가슴막액에서 PML-RARA 양성전골수구가발견된예

Conventional Cytogenetics and Fluorescence In Situ Hybridization in Persistent Cytopenias and Myelodysplastic Syndromes in Childhood

FISH and PNA-FISH. FISH and PNA-FISH. Stochastic effect. Radiation and cancer. 1) chromosome 2) FISH 3) PNA-FISH. Chromosome translocations.

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic

Extramedullary precursor T-lymphoblastic transformation of CML at presentation

Form 2011 R4.0: Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data

ACMG/CAP Cytogenetics CY

AML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen

Cytogenetic and Molecular Evaluation in Myelodysplastic Syndrome and in Acute and Chronic Leukemia

REGISTRATION FORM 1 / 2

Analysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemia

CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma

7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, Eva Lengfelder

Mild Megakaryocyte Atypia in a Patient with Presumed Germline GATA2 Mutation, and Active Mycobacterial Infection.

2011: ALL Pre-HCT. Subsequent Transplant

Karyology. Preparation and study of karyotypes is part of Cytogenetics.

-19. -Mousa Salah. -Shahd Alqudah. -Dr Belal

CYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING

Risk Stratification in Childhood Leukemia

Chromosomal Abnormalities and Karyotypes Creating a Karyotype

TITLE: Identification of Chromosomes Alterations in Primary Breast Cancer Using Premature Chromosome Condensation

Hematology Unit Lab 2 Review Material

Cell Cycle Phase. Interphase (G 1, S, G 2 ) Mitotic Phase (M phase) Prophase. Metaphase. Anaphase. Telophase

Research Article Isochromosome 17q in Chronic Lymphocytic Leukemia

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

Case of the Quarter Aug Daimon Simmons, MD, PhD, Paola Dal Cin, PhD, and Frank Kuo, MD, PhD

MS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD

Acute promyelocytic leukemia with the translocation t(15;17)(q22;q21) associated with t(1;2)(q42~43;q11.2~12): a case report

Blast Phase Chronic Myelogenous Leukemia

Molecular Hematopathology Leukemias I. January 14, 2005

2013 AAIM Pathology Workshop

Transcription:

CASE REPORT Acute Promyelocytic Leukemia with i(17)(q10) Junki Inamura 1, Katsuya Ikuta 2, Nodoka Tsukada 1, Takaaki Hosoki 1, Motohiro Shindo 2 and Kazuya Sato 1 Abstract We herein report a rare chromosomal abnormality observed in an acute promyelocytic leukemia (APL) patient. She had several APL derivative clones including a clone with i(17)(q10) abnormality, which consists of two kinds of structural abnormalities, a cryptic translocation of t(15;17) and an isochromosome of 17q. Although an obvious microscopic t(15;17) change was not observed on either arms of the isochromosome, PML/RARα fusion signals were detected on an interphase fluorescence in situ hybridization analysis. By several cytogenetic analyses of her bone marrow cells, it was confirmed that the i(17)(q10) clone was derived from the classic t(15;17) clone via another intervening clone, cryptic t(15;17). Key words: acute promyelocytic leukemia, cryptic translocation, i(17)(q10) (Intern Med 55: 3341-3345, 2016) () Introduction Acute promyelocytic leukemia (APL) is one of the most widely known hematological neoplasms and is associated with a typical chromosomal abnormality, the reciprocal translocation of t(15;17)(q22;q21). According to Cervera et al., additional chromosomal abnormalities are also seen in 28% of classic t(15;17)-positive APL patients (1). Although trisomy 8 or partial monosomy, i.e., 7q deletion, were representative in that study, an isochromosome change of 17q after the reciprocal translocation of t(15;17) was also occasionally observed, which was described as ider(17)(q10)t(15; 17) (2). This chromosome does not have a short arm (17p), but rather has two of the same arms derived from long arms (17q after the reciprocal translocation) on both sides of the centromere. In addition, APL cases without classic t(15;17) abnormalities have also been occasionally observed. According to Grimwade et al., the incidence of this finding in patients with APL is 9%, and the most common abnormality is cryptic t(15;17) (3). Because this abnormality involves the translocations of only submicroscopic fragments of chromosomes, the fusion gene PML/RARα exists on chromosome 15 or 17, without the detection of microscopic abnormalities on a routine chromosomal analysis. On the other hand, there are only few case reports of APL with i(17)(q10) consisting of both the cryptic t(15;17) and isochromosome of 17q. This condition does not have evidence of microscopic t(15;17) changes, although it does involve PML/RARα fusion genes (4-6). We herein report a case of APL with i(17)(q10). Frequent cytogenetic analyses performed at the time of diagnosis and during treatment revealed that the patient had several APL clones, including the i(17)(q10) clone as well as the classic t(15;17) clone. These findings helped us to speculate the developmental mechanism of i(17)(q10) in APL patients. Case Report A 74-year-old woman was incidentally noted to have pancytopenia on a regular blood examination during a follow-up of reflux esophagitis and was introduced to our hospital. A blood examination showed pancytopenia and abnormalities in fibrinolysis: WBC 1,200/μL (neutrophils 64%, lymphocytes 29%, monocytes 5%, eosinophils 2%, no abnormal cells were detected), Hb 10.0 g/dl, Plt 67 10 3 /μl and fibrin degradation products (FDP) 25.6 μg/ml (reference value: 0.0-5.0 μg/ml). However, neither the prothrombin time nor activated partial thromboplastin time was prolonged. Bone Department of Hematology/Oncology, Asahikawa Kosei Hospital, Japan and Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Japan Received for publication February 2, 2016; Accepted for publication February 24, 2016 Correspondence to Dr. Katsuya Ikuta, ikuta@asahikawa-med.ac.jp 3341

Table 1. Results of the Bone Marrow Analysis. Chromosomal analysis Interphase FISH analysis Fused signal Signal pattern Yellow:Red:Green Quantitative analysis (copies/ grna) At diagnosis 46,XX,i(17)(q10) [4] 46,XX [6] (Not performed) 4.2 10 4 day 14 46,XX,t(15;17) [1] 46,XX [19] 86% 2:1:1 (67%) 3:1:1 (19%) 0:2:2 (14%) 1.1 10 4 day 28 46,XX,t(15;17), add(17)(p13) [1] 46,XX [19] 47% 2:1:1 (42%) 2:1:2 (4%) 3:1:1 (1%) 0:2:2 (53%) 7.8 10 3 day 42 After 1st consolidation 46,XX [20] 0% 0:2:2 (100%) 5.2 10 2 (Not performed) 0% 0:2:2 (100%) Not detected Figure 1. A G-banding chromosomal analysis at the diagnosis. An isochromosome of 17q was detected, although there was no evidence of microscopic t(15;17) changes on either chromosome 15 or the isochromosome. The karyotype was described as 46,XX,i(17)(q10). marrow aspiration revealed hypocellular marrow (nuclear cell count: 5,000/μL), and 63.6% of the cells were abnormal cells with rich azurophilic granules or Auer bodies. The PML/RARα fusion gene was detected in the bone marrow cells on a reverse transcriptase-polymerase chain reaction () analysis, and she was diagnosed with APL. Induction therapy with tretinoin was started. Bone marrow examinations were performed to assess the effect of tretinoin on days 14, 28 and 42, including a G-banding chromosomal analysis, interphase fluorescence in situ hybridization (FISH) analysis and quantitative analysis. Interphase FISH analyses were performed using PML/RARα dual-color dualfusion probes. A yellow signal indicates a fusion signal of red and green signals, and a red or green signal indicates the PML or RARα gene, respectively. The results are shown in Table 1. At diagnosis, the chromosomal analysis showed only one type of abnormality, 46,XX,i(17)(q10), in four of 10 analyzed cells (Fig. 1). An interphase FISH analysis was not performed at that time. The quantitative analysis detected the PML/RARα fusion gene at 4.2 10 4 copies/ 3342

Table 2. Reported Cases of APL with i(17)(q10). References Age Sex 1 4 51F PML-RARA fused gene detection Interphase FISH Complete remission 2 5 44F Yes 3 6 10F 4 6 13F 5 6 42F b Our Interphase FISH 6 74F case Relapse Detection of classic t(15;17) clone Yes a No No Not described a The patient developed an acute monoblastic leukemia 10 months later with no evidence of relapse of APL. b The karyotype is 46,XX,del(7)(q31q33),i(17)(q10) No Yes No No Yes Yes No Yes No No Yes No Yes μg RNA. On day 14, the detected abnormal karyotype was 46,XX,t(15;17) in one of 20 analyzed cells, although the clone with 46,XX,i(17)(q10) was not detected according to the chromosomal analysis. According to the interphase FISH analysis, the rate of PML/RARα fusion-positive cells was 86%; two patterns were observed: yellow:red:green=2:1:1 (67%) and 3:1:1 (19%). The amount of fusion gene decreased to 1.1 10 4 copies/μg RNA according to a quantitative analysis. On day 28, the detected abnormal karyotype was 46,XX,t(15;17),add(17)(p13) in one of 20 analyzed cells on a chromosomal analysis. According to an interphase FISH analysis, the positive rate decreased to 47%; three patterns were observed: yellow:red:green=2:1:1 (42%), 2:1:2 (4%), 3:1:1 (1%). The amount of fusion gene also decreased to 7.8 10 3 copies/μg RNA using a quantitative analysis. On day 42, all of the abnormalities had disappeared on both the chromosomal and interphase FISH analyses, and the amount of fusion gene was decreased to 5.2 10 2 copies/μg RNA using a quantitative RT- PCR analysis. Three courses of consolidation chemotherapy were performed after 63 days of tretinoin treatment. Complete molecular remission was achieved after the first course of consolidation therapy. After consolidation therapy, maintenance therapy using tretinoin was performed, and the patient has maintained in remission for 54 months. Throughout the study period, the patient showed three types of abnormal karyotypes according to the chromosomal analyses, 46,XX,i(17)(q10), 46,XX,t(15;17) and 46,XX,t(15; 17),add(17)(p13), and three types of PML/RARα fusionpositive signal patterns on the interphase FISH analyses, yellow:red:green=2:1:1, 2:1:2 and 3:1:1. A clone with i(17) (q10) was also detected at diagnosis, although it disappeared, despite the appearance of the classic t(15;17) clone on day 14. Discussion It has been reported that acquired or constitutional isochromosomes originate from aberrant mitosis or meiosis (7, 8). Not longitudinal, but rather the transverse, division of the chromosome can yield a symmetrical chromosome with two identical arms in a daughter cell, which is referred to as an isochromosome. It has also been shown that the isochromosome of 17q, also described as i(17)(q10), is occasionally observed as an additional abnormality among various neoplasias, including hematological malignancies and solid tumors (9). Additionally, in cases of APL, the isochromosome of 17q after the translocation t(15;17), described as ider(17)(q10)t(15;17), has been occasionally reported. However, APLs associated with the i(17)(q10) clone with no evidence of microscopic t(15;17) are quite rare. As shown in Table 2, only six cases, including ours, have been described (4-6). The prognoses of these patients appear to be generally good. In case 2, the PML/RARA oncogene was detected using a PCR analysis; however, an interphase FISH analysis did not detect any fusion signals, although the precise reason was not described (5). In four of six patients, metaphase FISH analyses were performed, which can be used to directly clarify the location of the oncogene at discrete chromosomes. The oncogenes were located on chromosome 15 in one case (case 3) and on both arms of i(17) (q10) in three cases (cases 1, 4 and 5). The process by which the APL clone with i(17)(q10) appears remains unknown because of its extreme rarity. It might also be another reason that repetitive cytogenetic analyses were not performed, such that only limited information was available in past cases. In the present case, repetitive bone marrow tests revealed that the patient possessed several kinds of APL clones, including the clone with i(17)(q10) and the classic t(15;17) clone. The changes in the 3343

Intern Med 55: 3341-3345, 2016 Figure 2. Hypothesis of the i(17)(q10) clone derivation process. Clone A is the classic APL clone with t(15;17). Clone B is the so-called cryptic t(15;17) clone, which is derived from Clone A via retranslocation, and minute fragments are left on both chromosomes 15 and 17 reciprocally. Clone C is derived from Clone B via an isochromosome change on 17q. Both the normal clone and Clone B show a normal karyotype on chromosomal analyses. Both Clone A and Clone B show the same signal pattern, yellow:red:green=2:1:1, on interphase FISH analyses. Clone C shows i(17)(q10) with no evidence of translocation on a chromosomal analysis and shows yellow:red:green=3:1:1 signals on an interphase FISH analysis. ratios of such different clones enabled us to speculate the mechanism of development of i(17)(q10) at the diagnosis of APL. In particular, we hypothesize the derivation process, as outlined in Fig. 2. First, a reciprocal translocation between chromosomes 15 and 17 occurs, and the classic APL clone with t(15;17) appears. This clone is indicated as clone A. The interphase FISH signal pattern of clone A is yellow:red: green=2:1:1. Because the signals of PML and RARα are fused as one on chromosome 15 and one on chromosome 17, respectively, the results show two yellow signals. Thereafter, re-translocation between chromosomes 15 and 17 occurs on clone A, and clone B appears. Because the second breaking point is near to, but different from, the first breaking point, only minute chromosomal fragments are left on the respective chromosomes, although it again indicates a microscopically normal karyotype. We consider that the second breaking point is located on the same side of the respective t(15;17) juncture: either both proximal sides or both distal sides. As a result, on an interphase FISH analysis, the results continue to show two yellow signals, yellow:red: green=2:1:1, which is the same signal pattern as that for clone A. Clone B is the so-called cryptic t(15;17) clone. Finally, an isochromosome change of the long arm of chromosome 17 happens on clone B due to aberrant mitosis, and a new APL clone with isochromosome appears. This clone is clone C, which shows i(17)(q10) with no micro- scopic evidence of t(15;17) on a chromosomal analysis. However, this clone is positive for three fused signals according to an interphase FISH analysis; one of the three is from chromosome 15 and the other two are from the symmetric arms of i(17)(q10) (yellow:red:green=3:1:1). This signal pattern was detected in our case on days 14 and 28 (Table 1). Kim et al., who reported three i(17)(q10) cases, also hypothesized that the i(17)(q10) clone is derived from the cryptic t(15;17) clone (6), although they did not have sufficient data to prove the existence of cryptic t(15;17). However, according to our data, it was presumed that the i(17) (q10) clone is derived from the classic t(15;17) clone via another intervening clone, the cryptic t(15;17) clone. In the present case, the APL clone with cryptic t(15;17) was speculated to be derived from the classic t(15;17) clone. However, obtaining specific identification of the cryptic t(15;17) clone is impossible using a conventional cytogenetic analysis because it cannot be distinguished from normal cells based on a G-banding chromosome analysis or from classic t(15;17) cells based on an interphase FISH analysis. Therefore, there is a possibility that the existence of the cryptic t(15;17) clone is not recognized in many APL cases with both the classic t(15;17) clone and the cryptic t(15;17) clone. Even when classic APL is diagnosed, it is possible that the patient has both the classic and cryptic t(15;17) clones, especially in cases involving major quantita- 3344

tive deviations between the chromosomal analysis and interphase FISH analysis. Interestingly, although only the i(17)(q10) clone, not the classic t(15;17) clone, was detected at diagnosis in this case, the classic t(15;17) clone, not the i(17)(q10) clone, was conversely detected on day 14. We hypothesize that the patient s i(17)(q10) clone had a growth advantage and demonstrated hyperresponsiveness to tretinoin compared to the classic t(15;17) clone. If the second breaking point of both chromosomes 15 and 17 in the clone A is on the proximal side of the t(15;17) juncture, then the oncogene PML/RARα will move from chromosome 15 to 17. Hence, the two PML/RARA genes are on the i(17)(q10) chromosome. Due to the presence of dual oncogenes, the patient s i(17)(q10) clone might have been expanded mainly at diagnosis, whereas tretinoin possibly induced the i(17)(q10) clone to differentiate more rapidly than the t(15;17) clone. The cytogenetic analyses showed other abnormalities (Table 1). The 46,XX,t(15;17),add(17)(p13) detected on day 28 is presumably another derivative of the APL clone. The FISH signal pattern of yellow:red:green=2:1:2 noted on day 28 might also indicate the existence of another distinct APL clone, while no explicable karyotypes were detected in our analyses. The clinical course of our case appeared to be favorable, as in past reports of APLs with i(17)(q10), although the patient has such various APL clones. Therefore, the i(17) (q10) chromosome in cases of APL does not appear to be a poor prognostic factor, although a further accumulation of cases is necessary. The authors state that they have no Conflict of Interest (COI). References 1. Cervera J, Montesinos P, Hernández-Rivas JM, et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica 95: 424-431, 2010. 2. Manola KN, Karakosta M, Sambani C, et al. Isochromosome of der(17)(q10)t(15;17) in acute promyelocytic leukemia resulting in an additional copy of the RARA-PML fusion gene: report of 4 cases and review of the literature. Acta Haematol 123: 162-170, 2010. 3. Grimwade D, Biondi A, Mozziconacci MJ, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood 96: 1297-1308, 2000. 4. Lee GY, Christina S, Tien SL, et al. Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia. Cancer Genet Cytogenet 159: 129-136, 2005. 5. Huh J, Moon H, Chi H, Chung W. Acute promyelocytic leukemia with i(17)(q10) on G-banding and PML/RARA rearrangement by without evidence of PML/RARA rearrangement on FISH. Int J Lab Hematol 31: 372-374, 2009. 6. Kim M, Lim J, Kim Y, et al. The genetic characterization of acute promyelocytic leukemia with cryptic t(15;17) including a new recurrent additional cytogenetic abnormality i(17)(q10). Leukemia 22: 881-883, 2008. 7. de la Chapelle A. How do human isochromosomes arise? Cancer Genet Cytogenet 5: 173-179, 1982. 8. Darlington CD. Misdivision and the genetics of the centromere. J Genet 37: 341-364, 1939. 9. Mertens F, Johansson B, Mitelman F. Isochromosomes in neoplasia. Genes Chromosomes Cancer 10: 221-230, 1994. The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/ by-nc-nd/4.0/). 2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html 3345